Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) through its US-based subsidiary has entered into an Agreement to acquire from Sierra Analytics Inc (based in California, USA) all aspects of Sierra’s HDExaminer software business for $US430,000.

HDExaminer is used in Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), which is a powerful technique providing insight into protein dynamics. HDX-MS studies can be used to connect structure, behaviour, and function of a protein, between proteins and drugs, development of life-saving vaccines, as well as the cause and potential resolution of protein misfolding diseases.

Trajan has become a global leader in the automation of the HDX-MS technique and has also been the exclusive distributor of the HDExaminer since early 2018. HDExaminer enables the analysis of the protein structural information generated by the Mass Spectrometer.

Stephen Tomisich, Trajan CEO said “bringing ownership of HDExaminer into the Trajan family allows us to invest in the future development and enhancement of this powerful analytical platform. Together with our growing number of leading collaborators in the field of HDX-MS we expect to target several areas of the package to enable broader adoption of the technique along with enhancing the depth and value of protein structural information that can be revealed.”

HDExaminer revenues were approximately USD$350,000 in FY 2022, of which Trajan retained 35% as the exclusive distributor.

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited.

Contact:

Investors:
Rebecca Wilson
WE Communications
[email protected]

Media:
Amy Miller
WE Communications
[email protected]

About
Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 680 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.

investor.trajanscimed.com